Status:
RECRUITING
DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma
Lead Sponsor:
Barnet Dulaney Perkins Eye Centers
Collaborating Sponsors:
Alcon, a Novartis Company
Conditions:
Open Angle Glaucoma (OAG)
Eligibility:
All Genders
30+ years
Brief Summary
DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.
Detailed Description
DSLT enables newly diagnosed patients to remain well controlled and off medications
Eligibility Criteria
Inclusion
- Primary open angle glaucoma
- Patients age 30 or greater with an IOP of 18-26 mmHg
- Mild to moderate POAG patients (mild or moderate according to the AAO PPP Guidelines)
- DSLT procedure
Exclusion
- History of prior glaucoma treatment - this includes past medication use (in either eye), previous lasers or incisional surgery
- Angle closure patients
- Ocular Hypertension
- Baseline VF MD of worse than -12dB
- Uncontrolled systemic microvascular disease (eg. HTN, DM)
- Subjects with peri-limbal findings (e.g. melanosis, tumors, extensive pterygium, significant senile arcus and pterygium)
Key Trial Info
Start Date :
March 31 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT06933836
Start Date
March 31 2025
End Date
December 31 2027
Last Update
April 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barnet Dulaney Perkins Eye Centers
Mesa, Arizona, United States, 85206